cyrilzakka/clinical-trials huggingface dataset:
Effects of Hip Strengthening Training in Volleyball Players

In order to examine the effects of hip strength training on upper extremity function and performance, 60 healthy volleyball players with an age range of 13 to 40 years will be included in our study. Shoulder joint range of motion, shoulder and hip muscle strength, upper extremity functional performance, and spike speed will be evaluated. Participants will be randomly divided into 2 groups as Training Group (TG) (will receive 6-week, 3 days a week, hip strength training in addition to their sport-specific training) and Control Group (CG) (will continue their sport-specific training).

Evaluations will be repeated 3 times before exercise training, after 6 weeks of exercise training, and at the 12th week, and the results will be analyzed.

60 volleyball players will be included in our study. Assessments: 1. In the evaluation of upper extremity function and performance; strength of the shoulder internal and external rotator muscles will be measured with a hand-held dynamometer, shoulder internal and external rotation joint range of motion with a digital inclinometer, finally functional performance with closed kinetic chain upper extremity stability test and spike speed with a speed gun. 2. strength evaluation of the hip abductor, extensor, and external rotator muscles with a hand-held dynamometer. Participants will be randomly divided into 2 groups of 30 participants. The Training Group (TG) will receive 6 weeks of hip abduction, extension, and external rotation strengthening training in addition to their sport-specific training. Strengthening exercises will be done 3 days a week and every other day with a physiotherapist. Control Group (CG); will continue their sport-specific training. Evaluations will be repeated 3 times (before exercise training, after 6 weeks of exercise training, and at the end of the 12th week) and the results will be analyzed.

Eligibility Criteria:
Inclusion Criteria:

* Being between the ages of 13-40
* Volunteer to participate,
* To be training at least 2-3 session a week,
* Having played volleyball for at least 3 years, actively participating in training and competitions,
* To be able to complete all the evaluations to be made in the study

Exclusion Criteria:

* Having a systemic musculoskeletal disease,
* The occurrence of pain during the evaluations,
* History of fracture, instability or surgery in the last 6 months,
* Having an upper, lower extremity or spine injury (acute and/or active) in the last 6 months,
* Being away from sports for the last 6 months due to pain
Ultrasound Guided Arterial Puncture

The main purpose of the study is to evaluate whether the routine use of ultrasound guided arterial puncture can increase the proportion of patients who only needs one puncture attempt in order to successfully extract enough blood to make an arterial blood gas analysis, when ultrasound guided arterial puncture is compared to conventional arterial puncture technique.


Eligibility Criteria:
Inclusion Criteria:

* Patient admitted or treated in the acute emergency department
* Indication for a arterial blood gas analysis, according to the physician responsible for the patient's hospital stay / treatment

Exclusion Criteria:

* Patient age \< 16 years
Relative Effects and Predictive Models of Contemporary Upper Limb Training Programs in Stroke Patients

The findings of this study will advance movement reorganization mechanism underlying treatment approaches and clinical intervention techniques. These findings may inform rehabilitation professionals about which treatment approach is superior to another one in certain aspect of outcome and who can benefit most from certain treatment approach. Accordingly, the results of this project may help us move quickly to design and develop efficient and effective rehabilitation programs for individualized patients.

The first purpose is to investigate the relative effects of modified constraint-induced therapy (mCIT) vs. bilateral isokinematic training (BIT) vs. traditional or therapist-based training (TR) on movement reorganization, motor performance, functional ability, and quality of life (QoL) immediately and six months later after treatment delivered at hospitals. Movement reorganization will be evaluated by kinematic instrument. Motor performance, functional ability, and QoL will be assessed using clinical assessment tools. By the same token, we also investigate the relative effects of these two approaches delivered at home. The second purpose is to study whether home-based mCIT is efficacious in various aspects of outcomes described above immediately and six months later following treatment, compared to home-based TR, and hospital-based mCIT and TR.We also study the same question regarding home-based BIT efficacy. The third purpose is to establish predictive models to predict functional and QoL outcomes immediately and six months later following mCIT and BIT.

Eligibility Criteria:
Inclusion Criteria:

* the onset duration more than 6 months
* Brunnstrom stage III above for the proximal part and distal part of UL
* no serious cognitive deficits
* no balance problems sufficient to compromise safety when wearing the project's constraint device
* no excessive spasticity in any of the joints of the affected UL exclusion criteria:
* a score of less than 24 on the Mini Mental State Exam
Autologous Osteoperiosteal Transplantation for the Treatment of Severe Osteochondral Lesions of the Talus

The goal of this clinical trial is to establish a multicenter prospective cohort of patients with severe osteochondral lesion of the talus (OLT), evaluate the clinical efficacy of autologous osteoperiosteal transplantation and the incidence of postoperative donor-site morbidity. The main questions it aims to answer are:

Does autologous osteoperiosteal transplantation have good clinical outcomes in the treatment of severe OLT? Does autologous osteoperiosteal transplantation treat severe OLT with fewer postoperative complications?

Participants will:

Undergo autologous osteoperiosteal transplantation for OLT Receive clinical follow-up 3, 6, 12, and 24 months after surgery and answer scales of ankle function assessment Take CT and MRI preoperatively and 12 and 24 months after surgery


Eligibility Criteria:
Inclusion Criteria:

* Chronic ankle pain, diagnosed as Osteochondral Lesions of the Talus (OLT);
* Hepple V OLT on the medial side of the talus or the diameter of the lesion ≥ 8 mm;
* Conservative treatment of at least 3 months fails to relieve symptoms;
* Willingness to voluntarily participate in the trial and to sign informed consent.

Exclusion Criteria:

* Varus or valgus deformity of the ankle of more than 5 degrees;
* Grade III injury of the lateral collateral ligament of ankle;
* Chronic synovitis (rheumatoid arthritis, pigmented villous nodular synovitis, etc.);
* Joint fibrosis, stiffness, and significantly restricted range of motion;
* Evidence of moderate to severe knee osteoarthritis on plain radiographs;
* Failure to complete the rehabilitation protocol as required;
* Patient medically not fit for surgery, radiographs or MRI;
* For women, pregnant, planning to be pregnant or lactating.
A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise

During this study, your child will need to attend up to 5 office visits and maintain regular telephone contact with the clinic. Certain office visits will include physical exams, medical history review, exercise challenge test (walking/running on a treadmill), electrocardiogram (ECG) tests, and lung function tests. All study related medications and medical examinations are provided at no cost. All study drugs are currently available by prescription to patients 4 years and older.


Eligibility Criteria:
Inclusion criteria:

* Diagnosed with persistent asthma for 3 months or longer.
* Experience worsened asthma symptoms during physical activity.
* Using or used an inhaled steroid for the last 4 weeks or longer (such as Aerobid, Azmacort, Flovent, Pulmicort, QVAR, or Vanceril).

Exclusion criteria:

* Used systemic steroids as either liquids, pills, or injections to treat asthma within the last 3 months.
* Have only intermittent, seasonal, or exercise induced asthma, and not persistent asthma.
* Admitted to a hospital within the last 6 months due to asthma symptoms.
* Any poorly controlled medical conditions that may make study participation unsafe or inappropriate in the opinion of the study physician (such as cystic fibrosis, congenital heart disease, insulin dependent diabetes, glaucoma, drug allergies, etc.).
* The study physician will evaluate other medical criteria.
Long-term Follow-up Study of Subjects Who Completed Clinical Studies 755.1100_FA, 810.1100_FA, or 1064.1100_FA

This study evaluates the safety, effectiveness, and maintenance of effect of a novel topical silver particle solution (Sienna 755.1100, 810.1100, or 1064.1100) used in conjunction with a laser for the treatment of Acne Vulgaris.


Eligibility Criteria:
Inclusion Criteria:

* Subject has participated in study 755.1100_FA, 810.1100_FA, or 1064.1100_FA and fulfilled that study's exit criteria (ie, completion of the final visit \[visit 7\] of that study).
* Subject has followed predecessor study restrictions prior to study entry.
* Subject is able to provide informed consent and Health Insurance Portability and Accountability Act (HIPAA); minors will in addition have parent or legal guardian provide consent.
* Subject is willing to comply with the schedule, procedures, and restrictions of the study.

Exclusion Criteria:

* Subjects who have had any treatments or conditions (eg, pregnancy or metabolic disease) that may affect assessment of the safety or efficacy since enrollment in the predecessor study.
Nutritional Status of Cerebral Palsy Patients in Turkey

This is a single visit, non-interventional, cross sectional study about risk factors, etiology, nutritional status and feeding methods in CP patients.


Eligibility Criteria:
Inclusion Criteria:

* Subject is greater than/equal to 12 months and less than 19 years of age.
* Subject is diagnosed with cerebral palsy (CP) by a physician.

Exclusion Criteria:

* Subject presents with genopathies, cardiopathies, hypothyroidism or any pathology not related to CP.
* Subject is diagnosed with CP of postnatal origin.
* Subject has other concomitant diagnoses.
Digital Health Game as an Intervention Supporting Tobacco-related Health Literacy in Early Adolescents

This feasibility study evaluates acceptability and preliminary effectiveness of a digital health game as an intervention supporting tobacco-related health literacy in 10- to 13-year-old early adolescents. One third of the study participants will receive the health game, on third a web page with similar content and one third will act as a control group without intervention.


Eligibility Criteria:
Inclusion Criteria:

* Goes to school at 4th, 5th or 6th grade
* Understands and can communicate either in Finnish, Swedish or English
* Has daily access to either a smart phone or tablet computer during free time

Exclusion Criteria:

* Takes part to specialized education
Comparative Evaluation of the McGrath Videolaryngoscope and the Direct Laryngoscopy for Tracheal Intubation in the Prehospital Setting

In the prehospital setting, the risk of difficult intubation and life-threatening complications is increased under particular conditions due to the environment or the frequent instability of patients.

To limit this risk procedures and devices to ease and secure tracheal intubation must be developped and integrated.

As the prevalence of complications increase with the number of attempts of intubation, one strategy is to facilitate the intubation technic itself.

Direct laryngoscopy with Macintosh blades is the standard device commonly used in first place for tracheal intubation.

Other devices are available and used, mostly for difficult intubation, included videolaryngoscopy. This device has been used and studied for years now. Allowing a better view and glottic visualisation, videolaryngoscopy could increase the first-pass success rate.

Among all videolaryngoscopes, the McGrath videolaryngoscope is the most similar device to the standard Macintosh laryngoscope. It is light, compact, with a screen directly linked to the handle, easy to use and offering excellent view. Its usability and efficacy make it a device of choice for the prehospital setting and worth further clinical trials to define its place in the airway strategy.

Hypothesis: In the prehospital setting, the use of McGrath videolaryngoscope as the primary device for tracheal intubation could facilitate tracheal intubation and decrease the number of attempts of intubation and complications.

The objective of our study is to determine if the use of McGrath videolaryngoscope increase the rate of successful first-pass intubation in the prehospital setting compared to direct view Macintosh laryngoscopy.

The primary outcome is the rate of successful intubation at the first attempt. One attempt is defined as an advancement of the tube towards the glottis during a laryngoscopy ; every new try even during the same laryngoscopy is considered as a new attempt.

Successful intubation is confirmed by the visualisation of 6 waves of EtCO2.


Eligibility Criteria:
Inclusion Criteria:

* Age more than 18
* Indication of orotracheal intubation
* Operators trained to the use of the McGrath

Exclusion Criteria:

* Pregnancy
* No insurance
* Major patient under guardianship or curatorship
Shared Decision Making in Graves Disease - Graves Disease (GD) Choice

The investigators' decision aid for patients with GD, GD Choice, will be the result of a user-centered participatory action research involving) synthesis of the best available evidence from the literature and real-world registry experience, ii) input and involvement of patients, clinicians and other stakeholders, iii) direct observation of encounters and iv) extensive field-testing. The goal is to create a decision aid that will be rigorously evidence-based, clear and complete, able to be used by clinicians with minimal training time, while satisfying extant standards for rigorous high-quality shared decision making tools.


Eligibility Criteria:
Inclusion Criteria:

* Adults ≥ 18 years
* Diagnosis of Graves Disease
* Appointment with endocrinologist to discuss treatment options for Graves Disease

Exclusion Criteria:

* Major barriers to participate in shared decision making or to providing informed consent (i.e. dementia, severe hearing or visual impairment)
A Study of Meditation as a Treatment for Epilepsy

Epileptic seizures may occur at times of stress and commonly increase life stress. This study will evaluate whether meditation improves seizure control and quality of life for individuals with uncontrolled epilepsy.

Individuals who have uncontrolled epilepsy commonly experience disability, depression, anxiety and injuries from seizures. For such individuals, ideal treatments should improve quality of life through control of seizures and improved emotional state. Meditation with cultivation of emotional balance is known to improve emotional state and may also benefit seizure control in some individuals. In this study, individuals with uncontrolled epilepsy will receive detailed training in meditation to determine whether the training leads to improvements in seizure control and various measures of emotion and quality of life.

Eligibility Criteria:
Inclusion Criteria:

* 6 or more seizures per month
* ability to participate in meditation
Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex

The purpose of this study is to evaluate and compare the effect of two dosing regimens, BID versus TID dosing, of an Exploratory Vehicle (EV) on meibomian gland dysfunction (MGD) in patients with Demodex lid infestation.

This is a prospective, randomized controlled, three-arm, investigator- and interpreter-masked study. This study is intended to compare the effect of two dosing regimens of an exploratory vehicle on meibomian gland dysfunction (MGD) in participants with Demodex lid infestation. Approximately 12 participants will be enrolled in each arm. The administration period will last for approximately 85 days.

Eligibility Criteria:
Key Inclusion Criteria:

* Be willing to sign the informed consent and deemed capable of complying with the requirements of the study protocol
* Meets all of the following criteria in at least one eye: have more than 10 lashes with collarettes present on the upper lid; have the presence of one or more mites with lash epilation of the upper and lower lids; have evidence of meibomian gland dysfunction; have at least mild erythema of the lower lid; have a tear breakup time of less than 10 seconds; and have intact partial to full meibomian glands in at least 33% of the total meibomian gland area of the lower lid

Key Exclusion Criteria:

* Have used lid hygiene products within 7 days of Day 1 or unwilling to forego the use of lid hygiene products during the study
* Have used systemic antihistamines within 30 days of Day 1
* Have used artificial eyelashes, eyelash extensions, or had other cosmetic eyelash or eyelid procedures within 7 days of Day 1 or be unwilling to forego their use during the study
* Contact lens wear within 7 days of Day 1 or unwilling to forego contact lens wear for the duration of the study
* Be pregnant or lactating at Day 1
Effect of Probucol and/or Cilostazol on Mean IMT in Patients With Coronary Heart dIsease

The purpose of this study is to evaluate the additional effect of probucol or concomitant administration of cilostazol and probucol on mean carotid artery intima-media thickness (mean IMT) at year 1, 2, and 3.

Hyperlipidemic patients who are currently receiving HMGCoA reductase inhibitors(Statins) will be randomized Group A(Control), Group B(Probucol only added group) or Group C(Probucol and cilostazol added group) . Randomization will be done by the minimization method, controlling for the following factors: Country(Korea vs China) and max IMT (≥2.0mm vs.\<2.0mm).

Group A : HMGCoA reductase inhibitor continued

Group B : HMGCoA reductase inhibitor continued + Probucol 250 mg PO, BID

Group C : HMGCoA reductase inhibitor continued + Probucol 250 mg PO, BID +Cilostazol 100 mg PO, BID

Eligibility Criteria:
Inclusion Criteria:

* 1) Subjects who are at least 20 y of age at the time of informed consent (male or female)
* 2) Subjects with coronary heart disease longer than 3 months.
* 3) Subjects being treated with HMGCoA reductase inhibitors(Statins)
* 4) Subjects with an max IMT equal to or greater than 1.2 mm
* 5) Subjects with an LDL-Cholesterol less than 200mg/dl
* 6) Subjects whose voluntary written informed consent is obtained for participation in this study

Exclusion Criteria:

* 1) Subjects who took probucol within 6 months before participation of the study
* 2) Subjects who took cilostazol within 3 months before participation of the study
* 3) Subjects with a history of hypersensitivity to probucol or cilostazol
* 4) Subjects with homozygous familial hyperlipidemia\*
* 5) Subjects with a triglyceride ( TG) level greater than 400mg/dL at screening
* 6) Subjects with uncontrolled diabetes : HbA1c level greater than 9%
* 7) Subjects with New York Heart Association (NYHA) classification: Class Ⅲ and Ⅳ
* 8) Subjects with a QTc interval greater than 450msec(male) 470msec(female)
* 9) Subjects with serious ventricular arrythmias (frequent episodes of multifocal ventricular extrasystole)
* 10) Subjects with atrial fibrillation (including paroxysmal AF)
* 11) Subjects with unstable angina
* 12) Subjects with liver and kidney functions that satisfy the following criteria - AST or ALT \>100 IU/L, serum creatinine \>1.5 mg/dL
* 13) Subjects who are participating in another clinical trial
* 14) Subjects with pregnant or possibly pregnant without appropriate contraception control. Appropriate contraception control means that Oral contraception for greater than 4 weeks, surgical contraception including loop insertion, condom use etc. Women who has no possibility of pregnancy because of surgery or menopause should not be regarded the subject with possibly pregnant
* 15) Subjects with clinically significant disorders of blood coagulation
* 16) Subjects who are not considered by the physicians to be appropriate to participate in this trial for any other reason
Development and Validation of Performance Metrics for Cardiac Device Implant Procedures

Cardiac Device implantation includes implantation of pacemakers, implantable defibrillators and Cardiac resynchronisation Therapy (CRT) devices. These are well-established treatments for selected with heart rhythm abnormalities and heart failure.

In the past, trainee doctors had the opportunity to perform many procedures and learn on the patient. This is no longer the case due to a change in training schedules and working times as well as patient safety mandates. Progression based training with the use of simulators has been proven to be effective in training and in order to use this methodology, the procedure needs to be well defined.

Despite its worldwide adoption, a standardized procedure has never been defined in detail and agreed upon and the cardiac device implant technique varies with the operator.

The purpose of the research is to establish the metrics (operational definitions) necessary to characterize a reference Cardiac Device implant procedure.

The purpose of the research is to establish the metrics (operational definitions) necessary to characterize a reference Cardiac Device implant procedure, to seek consensus from experienced device implanters on the appropriateness of the steps as well as errors identified, and to determine if such validated performance metrics are a valid assessment tool with the ability to discriminate between the performances of experienced and novice implanters.

These validated metrics will potentially serve as an educational and training tool to improve and quality assure Cardiac device implant training.

The steps involved in characterising a reference procedure are as follows:

1. Define the implant procedure in quantifiable steps (already performed)
2. Seek consensus and agreement by an independent panel on the steps (already done).
3. Video record routinely performed device implants by experienced and novice physicians.
4. Reviewing and scoring the video recorded procedures to verify that the metrics distinguish between a novice and an expert cardiac device performance.

Eligibility Criteria:
Inclusion Criteria:

Patients eligible for a cardiac device implant as per current European Society of Cardiology guidelines.

Exclusion Criteria:

Patient\< 18 y of age. Patients unable to provide informed written consent for the study.

-